Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Engineered Virus Designed to Fight Triple-Negative Breast Cancer

By BiotechDaily International staff writers
Posted on 11 Feb 2014
Image: Breast cancer cell. Triple-negative breast cancer is an aggressive disease with few therapeutic options. Patients with such tumors can be treated only with chemotherapy (Photo courtesy of the National Cancer Institute).
Image: Breast cancer cell. Triple-negative breast cancer is an aggressive disease with few therapeutic options. Patients with such tumors can be treated only with chemotherapy (Photo courtesy of the National Cancer Institute).
Scientists have found a possible cure for one of the most deadly, aggressive, and least treatable forms of breast cancer called triple-negative breast cancer (TNBC). In laboratory research involving human cancer cells, scientists exploited a virus comparable to the one that helped eradicate smallpox to persuade cancer cells to generate a protein that makes them disposed to radioactive iodine.

The new findings were published in the February 2014 issue of Federation of American Societies for Experimental Biology’s the FASEB Journal. “We hope that the recent developments in genetic engineering, virology, and targeted radiotherapy will soon translate into an entire class of innovative oncolytic virotherapies for the treatment of deadly cancers,” said Yuman Fong, MD, a researcher involved in the work from the department of surgery at Memorial Sloan-Kettering Cancer Center (New York, NY, USA).

In the study, Dr. Fong and colleagues effectively infected and destroyed TNBC cells using a Vaccinia virus. Furthermore, the researchers were also able to utilize the virus to cause infected cancer cells produce a cell surface protein called hNIS (human Na+/I- symporter) that typically is used to concentrate iodine in thyroid cells. Expressed in thyroid cancer, the hNIS protein is why most thyroid cancers can be cured or successfully treated with a small dose of radioactive iodine, killing thyroid cancer cells expressing hNIS in the process. Equipped with the ability to compel TNBC cells to produce this protein, researchers now have a way to deliver anticancer treatments to this lethal and resistant form of cancer.

“This is an important and significant discovery that basically combines proven cures for two other diseases,” said Gerald Weissmann, MD, editor-in-chief of the FASEB Journal. “Even more exciting is that the effects of this virus and radioactive iodine are well known in people, hopefully reducing the amount of time it will take for it to reach the clinic.”

Related Links:

Memorial Sloan-Kettering Cancer Center



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.